Marshall Wace, LLP Kymera Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 376,562 shares of KYMR stock, worth $18.3 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
376,562
Previous 572,926
34.27%
Holding current value
$18.3 Million
Previous $23 Million
51.2%
% of portfolio
0.02%
Previous 0.04%
Shares
6 transactions
Others Institutions Holding KYMR
# of Institutions
160Shares Held
63.1MCall Options Held
22.6KPut Options Held
14.4K-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$311 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$292 Million2.38% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.35MShares$261 Million21.28% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$251 Million4.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$235 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.66B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...